The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution   Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)     Employment - Avacta Life Sciences Leadership - Avacta Life Sciences Stock and Other Ownership Interests - Avacta Life Sciences   Employment - Institute of Cancer Research Consulting or Advisory Role - Amalus Therapeutics; Carrick Therapeutics; Dania Therapeutics; DeuterOncology; Ellipses Pharma; PEGASCY; PharmEnable Research Funding - Avacta Life Sciences (Inst); Chugai Pharma (Inst); Verastem (Inst); Verastem (Inst)   Employment - Orra Group Leadership - Orra Group Stock and Other Ownership Interests - amidebio Consulting or Advisory Role - artiva; Avacta Life Sciences; cali; SignPath Pharma; Sonoma Biotherapeutics; Tanabe Research; Tango Therapeutics; vaxthera Travel, Accommodations, Expenses - Orra Group   Employment - ThinkQ2   Employment - CellCentric (I) Stock and Other Ownership Interests - CellCentric (I) Honoraria - Roche Speakers' Bureau - Roche Research Funding - AstraZeneca (Inst); Avacta Life Sciences (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cancer Research UK (Inst); Eisai (Inst); Loxo/Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst) Patents, Royalties, Other Intellectual Property - CUPiD Methylation assay. Patent application has now been filed at the UKIPO. The patent application number is GB2317261.2 (Inst) Travel, Accommodations, Expenses - Roche; SERVIER (OPTIONAL) Uncompensated Relationships - Roche   Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Boehringer Ingelheim; Curadev; Daiichi Sankyo; Deciphera; EMD Serono; Ikena Oncology; inhibrx; Ipsen; Ratio; Recordati; SynOX Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst) Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03   Honoraria - Sanofi Consulting or Advisory Role - Avacta Life Sciences; Rgenta   Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst) Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst) Research Funding - Adaptimmune (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Bayer (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Owkin (Inst); Pfizer (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Sotio (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst) Expert Testimony - iOnctura (Inst); Medivir (Inst) Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre; Roche Other Relationship - Genmab (Inst)   Honoraria - Daiichi Sankyo; Eisai; Gilead Sciences; MSD; Novartis; Pfizer Consulting or Advisory Role - Daiichi Sankyo; Eisai; Pfizer Speakers' Bureau - Daiichi Sankyo; Eisai; MSD; Pfizer Research Funding - AstraZeneca; Avacta Life Sciences; Pfizer Travel, Accommodations, Expenses - Eisai; Gilead Sciences; MSD Oncology; Pfizer   Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Sanofi/Aventis Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Benevolent AI; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Incyte; Nerviano Medical Sciences; Novartis; Novartis Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst) Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology Other Relationship - Alligator Bioscience; AstraZeneca; GlaxoSmithKline; PharmaMar; Sotio   Honoraria - Horizon CME Consulting or Advisory Role - AffyImmune Therapeutics; Cantor Fitzgerald; Day One Biopharmaceuticals; GlaxoSmithKline; Immunome; InhibRx; Johnson & Johnson/Janssen; National Cancer Institute; Pyxis; Remix Therapeutics; Rgenta Therapeutics; Takeda Speakers' Bureau - Miami Cancer Research Center; Mt. Sinai; New York University (NYU); Northwell Health; Physicans' Education Resource Research Funding - Astellas Pharma; AstraZeneca; Avacta Life Sciences; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN Travel, Accommodations, Expenses - Hookipa Pharma; Lepu Biopharma; Remix Therapeutics Other Relationship - Hookipa Biotech; Lepu Biopharma (OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; HPV Cancer Alliance; International Thyroid Oncology Group   Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Johnson & Johnson/Janssen; Labcorp Drug Development; Pyxis; Raptor Pharmaceuticals; Regeneron; Rgenta Research Funding - Avacta Life Sciences (Inst); Bicara Therapeutics (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Seagen (Inst); Viracta Therapeutics (Inst) Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year Travel, Accommodations, Expenses - Bicara Therapeutics   Speakers' Bureau - Eisai Travel, Accommodations, Expenses - Pfizer